Sorry, your browser does not support JavaScript. Some of the features on this website require Javascript to be enabled.
Important Safety Information
Serious, life-threatening, and/or fatal respiratory depression has occurred. Monitor closely, especially upon initiation or following a dose increase. Due to the risk of fatal respiratory depression, FENTORA is contraindicated in opioid non-tolerant patients and in management of acute or postoperative pain, including headache/migraines. Read More Important Safety Information

Dosing for FENTORA

  • FENTORA is not bioequivalent to other fentanyl products. Do not convert patients on a mcg per mcg basis from other fentanyl products
  • For new patients not converting from ACTIQ®/OTFC (oral transmucosal fentanyl citrate), always initiate FENTORA buccal tablet at 100 mcg
  • Patients converting from ACTIQ®/OTFC may need a different starting dose*†
Table presenting initiation doses of FENTORA® (fentanyl buccal tablet) CII for patients converting from ACTIQ/OTFC
  • Patients and their caregivers must be instructed that FENTORA contains a medicine in an amount that can be fatal to a child
  • FENTORA is not recommended for use in patients who have received MAO inhibitors within 14 days, because severe and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics
  • Administer FENTORA with caution to patients with hepatic or renal impairment


Titrating with FENTORA

Initiate at 100 mcg and titrate to a successful dose*

*A successful dose provides adequate analgesia with tolerable side effects.
Image showing how to administer FENTORA 100-mcg tablets in the buccal mucosa during titration

Titrate using 200 mcg tablets for doses of 400 mcg or greater*

*A successful dose provides adequate analgesia with tolerable side effects.
Image showing how to administer FENTORA 200-mcg tablets in the buccal mucosa during titration
Titration to a therapeutic dose must be achieved using buccal administration
(in the buccal cavity, above a rear molar, between upper cheek and gum) before
starting sublingual administration in maintenance
  • If breakthrough pain is not relieved after 30 minutes, patients may take only 1 additional dose of the same strength for that episode (no more than 2 doses per episode)
  • Patients must wait at least 4 hours before treating another breakthrough pain episode with FENTORA
  • Patients should record their use of FENTORA over several episodes of breakthrough pain and discuss their experience with their physician to determine if a dosage adjustment is required
  • During titration, a dose of FENTORA may include administration of 1 to 4 tablets of the same dosage strength. No more than 4 tablets should be used simultaneously
  • It is important to minimize the number of strengths available to patients at any time to prevent confusion and possible overdose
  • Titrate FENTORA cautiously in patients with chronic obstructive pulmonary disease or preexisting medical conditions predisposing them to respiratory depression and in patients susceptible to intracranial effects of CO2 retention

Once a successful dose of FENTORA is determined, maintain that dose using a single tablet, administered buccally or as an alternate route, sublingually (placing the tablet under the tongue).

70% of patients who found a successful FENTORA dose
following titration achieved optimal pain relief on doses
≥400 mcg in the pivotal trial
  • Use with other CNS depressants and cytochrome P450 3A4 inhibitors may increase depressant effects including hypoventilation, hypotension, and profound sedation. Consider dosage adjustments if warranted
  • For patients requiring discontinuation of opioids, a gradual downward titration is recommended because it is not known at what dose level the opioid may be discontinued without producing the signs and symptoms of abrupt withdrawal

Follow dosing instructions carefully:

  • Patients using FENTORA must continue using their around-the-clock opioids for persistent pain
  • If a breakthrough pain episode is not relieved after 30 minutes, patients may take only 1 additional dose of the same strength for that breakthrough pain episode (more than 2 doses per episode)
  • Patients must wait at least 4 hours before treating another breakthrough pain episode with FENTORA
  • On average, if a patient experiences more than 4 episodes of breakthrough pain per day, their around-the-clock opioid should be re-evaluated

IMPORTANT SAFETY INFORMATION

WARNING: LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; RISKS FROM CYTOCHROME P450 3A4 INTERACTION; RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; RISK OF MEDICATION ERRORS; ADDICTION, ABUSE, AND MISUSE; REMS; and NEONATAL OPIOID WITHDRAWAL SYNDROME

See full prescribing information for complete boxed warning.

  • Serious, life-threatening, and/or fatal respiratory depression has occurred. Monitor closely, especially upon initiation or following a dose increase. Due to the risk of fatal respiratory depression, FENTORA is contraindicated in opioid non-tolerant patients and in management of acute or postoperative pain, including headache/migraines.
  • Accidental ingestion of FENTORA, especially by children, can result in a fatal overdose of fentanyl. Keep out of reach of children. Ensure proper storage and disposal.
  • Concomitant use with CYP3A4 inhibitors (or discontinuation of CYP3A4 inducers) can result in a fatal overdose of fentanyl.
  • Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for use in patients for whom alternative treatment options are inadequate; limit dosages and durations to the minimum required; and follow patients for signs and symptoms of respiratory depression and sedation.
  • When prescribing, do not convert patients on a mcg per mcg basis from any other fentanyl product to FENTORA.
  • When dispensing, do not substitute with any other fentanyl products.
  • FENTORA exposes users to risks of addiction, abuse, and misuse, which can lead to overdose and death. Assess patient’s risk before prescribing and monitor closely for these behaviors and conditions.
  • FENTORA is available only through a restricted program called the TIRF REMS Access program. Outpatients, healthcare professionals who prescribe to outpatients, pharmacies, and distributors are required to enroll in the program.
  • Prolonged use of FENTORA during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated. If prolonged opioid use is required in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.

FENTORA is contraindicated in:

  • Opioid non-tolerant patients: Life-threatening respiratory depression and death could occur at any dose in opioid non-tolerant patients.
  • Significant respiratory depression.
  • Acute or postoperative pain including headache/migraine and dental pain, or acute pain in the emergency department.
  • Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment.
  • Known or suspected gastrointestinal obstruction, including paralytic ileus.
  • Known hypersensitivity (e.g. anaphylaxis) to fentanyl or components of FENTORA (e.g., anaphylaxis).

Life-Threatening Respiratory Depression in Patients with Chronic Pulmonary Disease or in Elderly, Cachectic, or Debilitated Patients: FENTORA-treated patients with significant chronic obstructive pulmonary disease or cor pulmonale, and those with a substantially decreased respiratory reserve, hypoxia, hypercapnia, or pre-existing respiratory depression are at increased risk of decreased respiratory drive including apnea, even at recommended dosages of FENTORA. Life-threatening respiratory depression is more likely to occur in elderly, cachectic, or debilitated patients because they may have altered pharmacokinetics or altered clearance compared to younger, healthier patients. Monitor such patients closely, particularly when initiating and titrating FENTORA and when FENTORA is given concomitantly with other drugs that depress respiration. Alternatively, consider the use of non-opioid analgesics in these patients.

Serotonin Syndrome with Concomitant Use of Serotonergic Drugs: Cases of serotonin syndrome, a potentially life-threatening condition, have been reported during concomitant use of FENTORA with serotonergic drugs. This may occur within the recommended dosage range. The onset of symptoms generally occurs within several hours to a few days of concomitant use, but may occur later than that. Discontinue FENTORA if serotonin syndrome is suspected.

Adrenal Insufficiency: Cases of adrenal insufficiency have been reported with opioid use, more often following greater than one month of use. If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. Wean the patient off of the opioid to allow adrenal function to recover and continue corticosteroid treatment until adrenal function recovers. Other opioids may be tried as some cases reported use of a different opioid without recurrence of adrenal insufficiency.

Severe Hypotension: FENTORA may cause severe hypotension including orthostatic hypotension and syncope in ambulatory patients. There is increased risk in patients whose ability to maintain blood pressure has already been compromised by a reduced blood volume or concurrent administration of certain CNS depressant drugs (e.g. phenothiazines or general anesthetics). Monitor these patients for signs of hypotension after initiating or titrating the dosage of FENTORA. In patients with circulatory shock, FENTORA may cause vasodilation that can further reduce cardiac output and blood pressure. Avoid the use of FENTORA in patients with circulatory shock.

Risks of Use in Patients with Increased Intracranial Pressure, Brain Tumors, Head Injury, or Impaired Consciousness: In patients who may be susceptible to the intracranial effects of CO2 retention (e.g., those with evidence of increased intracranial pressure or brain tumors), FENTORA may reduce respiratory drive, and the resultant CO2 retention can further increase intracranial pressure. Monitor such patients for signs of sedation and respiratory depression, particularly when initiating therapy with FENTORA. Opioids may also obscure the clinical course in a patient with a head injury. Avoid the use of FENTORA in patients with impaired consciousness or coma.

Risks of Use in Patients with Gastrointestinal Conditions: The fentanyl in FENTORA may cause spasm of the sphincter of Oddi. Opioids may cause increases in serum amylase. Monitor patients with biliary tract disease, including acute pancreatitis for worsening symptoms.

Increased Risk of Seizures in Patients with Seizure Disorders: The fentanyl in FENTORA may increase the frequency of seizures in patients with seizure disorders, and may increase the risk of seizures occurring in other clinical settings associated with seizures. Monitor patients with a history of seizure disorders for worsened seizure control during FENTORA therapy.

Risks of Driving and Operating Machinery: FENTORA may impair the mental or physical abilities needed to perform potentially hazardous activities such as driving a car or operating machinery. Warn patients not to drive or operate dangerous machinery unless they are tolerant to the effects of FENTORA and know how they will react to the medication.

Cardiac Disease: Intravenous fentanyl may produce bradycardia. Therefore, use FENTORA with caution in patients with bradyarrhythmias.

Application Site Reactions: Application site reactions occurred in 10% of patients in clinical trials and ranged from paresthesia to ulceration and bleeding.

MAO Inhibitors: FENTORA is not recommended for use in patients who have received MAO inhibitors within 14 days, because severe and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics.

Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics: Avoid use with FENTORA because they may reduce analgesic effect of FENTORA or precipitate withdrawal symptoms.

Patients with Renal or Hepatic Impairment: Administer FENTORA with caution.

Common Adverse Reactions (frequency ≥10%): nausea, dizziness, vomiting, fatigue, anemia, constipation, edema peripheral, asthenia, dehydration and headache.

Please see Full Prescribing Information.

Reference: 1. Fentora [package insert]. North Wales, PA: Teva Pharmaceuticals USA, Inc.; 2016.
FENTORA Savings Card
Help eligible patients receive their first month of FENTORA FREE, and $5 copays
FENTORA C.A.R.E. Team logo
The FENTORA C.A.R.E. Team provides dedicated support for copay savings, benefits verification, and prior authorization
Request a FENTORA Rep
Request a visit from a FENTORA representative